The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2017 | Molecular tools for lung cancer therapies
Charles Swanton, FRCP, BSc, PhD from the Francis Crick Institute, London, UK discusses the up and coming molecular tools in lung cancer. A subset of patients are at higher risk of disease recurrence after receiving first-line therapy, and it is crucial to develop successful second-line therapies for these patients. This interview was recorded at the annual meeting of the European Lung Cancer Conference (ELCC) 2017, Geneva, Switzerland.
